These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30113582)

  • 21. Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers.
    Lee JW; Pussegoda K; Rassekh SR; Monzon JG; Liu G; Hwang S; Bhavsar AP; Pritchard S; Ross CJ; Amstutz U; Carleton BC;
    Ther Drug Monit; 2016 Aug; 38(4):423-31. PubMed ID: 26960170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Further Investigation of the Role of
    Drögemöller BI; Brooks B; Critchley C; Monzon JG; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Hayden MR; Gelmon KA; Carleton BC; Ross CJD
    Clin Cancer Res; 2018 Apr; 24(8):1866-1871. PubMed ID: 29358504
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacogenetic analysis of irreversible severe cisplatin-induced nephropathy: a case report of a 27-year-old woman.
    de Jong C; Sanders S; Creemers GJ; Burylo AM; Taks M; Schellens JHM; Deenen MJ
    Br J Clin Pharmacol; 2017 Sep; 83(9):2120-2122. PubMed ID: 28560854
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacogenetic variants in TPMT alter cellular responses to cisplatin in inner ear cell lines.
    Bhavsar AP; Gunaretnam EP; Li Y; Hasbullah JS; Carleton BC; Ross CJ
    PLoS One; 2017; 12(4):e0175711. PubMed ID: 28406961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Common variants in ACYP2 influence susceptibility to cisplatin-induced hearing loss.
    Xu H; Robinson GW; Huang J; Lim JY; Zhang H; Bass JK; Broniscer A; Chintagumpala M; Bartels U; Gururangan S; Hassall T; Fisher M; Cohn R; Yamashita T; Teitz T; Zuo J; Onar-Thomas A; Gajjar A; Stewart CF; Yang JJ
    Nat Genet; 2015 Mar; 47(3):263-6. PubMed ID: 25665007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Genetic background of cisplatin induced ototoxicity].
    Jurajda M; Talach T; Kostřica R; Lakomý R; Kocák I; Cvanová M
    Klin Onkol; 2012; 25(3):184-7. PubMed ID: 22724567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer.
    Drögemöller BI; Monzon JG; Bhavsar AP; Borrie AE; Brooks B; Wright GEB; Liu G; Renouf DJ; Kollmannsberger CK; Bedard PL; Aminkeng F; Amstutz U; Hildebrand CA; Gunaretnam EP; Critchley C; Chen Z; Brunham LR; Hayden MR; Ross CJD; Gelmon KA; Carleton BC
    JAMA Oncol; 2017 Nov; 3(11):1558-1562. PubMed ID: 28448657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients.
    Olgun Y; Aktaş S; Altun Z; Kırkım G; Kızmazoğlu DÇ; Erçetin AP; Demir B; İnce D; Mutafoğlu K; Demirağ B; Ellidokuz H; Olgun N; Güneri EA
    Int J Pediatr Otorhinolaryngol; 2016 Nov; 90():64-69. PubMed ID: 27729156
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cisplatin-induced ototoxicity in pediatric solid tumors: the role of glutathione S-transferases and megalin genetic polymorphisms.
    Choeyprasert W; Sawangpanich R; Lertsukprasert K; Udomsubpayakul U; Songdej D; Unurathapan U; Pakakasama S; Hongeng S
    J Pediatr Hematol Oncol; 2013 May; 35(4):e138-43. PubMed ID: 23274376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leveraging large-scale datasets and single cell omics data to develop a polygenic score for cisplatin-induced ototoxicity.
    Miao DNR; Wilke MAP; Pham J; Ladha F; Singh M; Arsenio J; Luca E; Dabdoub A; Yang W; Yang JJ; Drögemöller BI
    Hum Genomics; 2024 Oct; 18(1):112. PubMed ID: 39380081
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cisplatin-induced hearing loss: the need for a long-term evaluating system.
    Yasui N; Adachi N; Kato M; Koh K; Asanuma S; Sakata H; Hanada R
    J Pediatr Hematol Oncol; 2014 May; 36(4):e241-5. PubMed ID: 24072246
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ototoxicity in children treated for osteosarcoma.
    Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
    Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hearing loss in Mexican children treated with cisplatin.
    Castelán-Martínez OD; Jiménez-Méndez R; Rodríguez-Islas F; Fierro-Evans M; Vázquez-Gómez BE; Medina-Sansón A; Clark P; Carleton B; Ross C; Hildebrand C; Castañeda-Hernández G; Rivas-Ruiz R
    Int J Pediatr Otorhinolaryngol; 2014 Sep; 78(9):1456-60. PubMed ID: 25037447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Ototoxicity of cisplatin].
    Kitoh R; Usami S
    Nihon Rinsho; 2015 Feb; 73 Suppl 2():480-5. PubMed ID: 25831807
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of Genetic Variation in
    Agema BC; Koolen SLW; With M; Doorn NV; Heersche N; Hoop EO; Visser S; Aerts JGJV; Bins S; Schaik RHNV; Mathijssen RHJ
    Genes (Basel); 2020 Mar; 11(4):. PubMed ID: 32230800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacogenetics of drug-induced ototoxicity caused by aminoglycosides and cisplatin.
    Lanvers-Kaminsky C; Ciarimboli G
    Pharmacogenomics; 2017 Dec; 18(18):1683-1695. PubMed ID: 29173064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of platinum-induced ototoxicity in pediatric patients in Quebec.
    Peleva E; Emami N; Alzahrani M; Bezdjian A; Gurberg J; Carret AS; Daniel SJ
    Pediatr Blood Cancer; 2014 Nov; 61(11):2012-7. PubMed ID: 24976616
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.
    Weinshilboum RM
    Cell Mol Neurobiol; 2006; 26(4-6):539-61. PubMed ID: 16807786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Detection of ototoxic effect of cisplatin with otoacoustic emission in testicular cancer patients].
    Biró K
    Magy Onkol; 2009 Sep; 53(3):279-83. PubMed ID: 19793694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variants in
    Wheeler HE; Gamazon ER; Frisina RD; Perez-Cervantes C; El Charif O; Mapes B; Fossa SD; Feldman DR; Hamilton RJ; Vaughn DJ; Beard CJ; Fung C; Kollmannsberger C; Kim J; Mushiroda T; Kubo M; Ardeshir-Rouhani-Fard S; Einhorn LH; Cox NJ; Dolan ME; Travis LB
    Clin Cancer Res; 2017 Jul; 23(13):3325-3333. PubMed ID: 28039263
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.